0000950170-24-011271.txt : 20240205 0000950170-24-011271.hdr.sgml : 20240205 20240205162956 ACCESSION NUMBER: 0000950170-24-011271 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240201 FILED AS OF DATE: 20240205 DATE AS OF CHANGE: 20240205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schaefer Thomas J. CENTRAL INDEX KEY: 0001960808 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37383 FILM NUMBER: 24596122 MAIL ADDRESS: STREET 1: 202 COUSTEAU PLACE STE 105 CITY: DAVIS STATE: CA ZIP: 95618 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Arcadia Biosciences, Inc. CENTRAL INDEX KEY: 0001469443 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE PRODUCTION - CROPS [0100] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 810571538 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 202 COUSTEAU PLACE STREET 2: SUITE 105 CITY: DAVIS STATE: X1 ZIP: 95618 BUSINESS PHONE: 530-756-7077 MAIL ADDRESS: STREET 1: 202 COUSTEAU PLACE STREET 2: SUITE 105 CITY: DAVIS STATE: CA ZIP: 95618 4 1 ownership.xml 4 X0508 4 2024-02-01 0001469443 Arcadia Biosciences, Inc. RKDA 0001960808 Schaefer Thomas J. C/O ARCADIA BIOSCIENCES, INC. 5950 SHERRY LANE, SUITE 215 DALLAS TX 75225 false true false false Chief Financial Officer false Common Stock 2024-02-01 4 P false 700 2.06 A 1419 D Reflects the purchase of 700 shares of the Issuer's common stock on 2/1/24 at a per share purchase price of $2.06 pursuant to participation in the Issuer's 2015 Employee Stock Purchase Plan ("ESPP"). This transaction is exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of Issuer's common stock. The amount includes the 2015 Employee Stock Purchase Plan ("ESPP") purchases, for the purchase periods from February 1, 2021 to February 1, 2024. These transactions were exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of Issuer's Common Stock on the date of each respective purchase. Thomas J. Schaefer, by Attorney-in-fact, Solaeta Chan 2024-02-05